GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), today told the investment community of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine. According to the press release, this completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, “The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH).”

“The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody,” commented Dr. Harriet

Cannabis Science Inc. is an emerging cannabis pharmaceutical company. Trading on the OTCBB, they are at the forefront of medical marijuana research and development. With headquarters in San Francisco, California, the company works with world authorities on phytocannabinoid science targeting critical illnesses. Phytocannabinoids - also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids - are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin produced in glandular structures known as trichomes and are most prevalent in the flowers of the female plants.

Cannabis Science, Inc.’s dedication is to the creation of cannabis-based medicines. The company adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. They are working to create these medicines both with and without psychoactive properties as well as treat disease and the symptoms of disease

Last month, Cannabis Science reported that patent filings are expected for